Health Insurance for Crohn's Disease: How to Choose a Plan

Choosing health insurance for Crohn's disease is not the same exercise as choosing a plan when you are generally well. The premium is the number the shopping site shows first, and for anyone on a biologic it is often the least important figure of the several that decide what the year costs. This guide covers the documents to open, the numbers to write down and the questions to ask before a deadline closes.

Key Takeaways

• IBD patients had direct costs of $22,987 per member per year versus $6,956 for matched controls, and out-of-pocket costs of $2,213 versus $979 (6)
• Fewer than 20 percent of those patients were on biologics, but they incurred 2 to 3 times the total annual cost of care (6)
• For the 2027 benefit year the ACA out-of-pocket cap is $12,000 self-only and $24,000 other than self-only, about 13.2 percent above the 2026 limits of $10,600 and $21,200 (1)
• Plans may apply a separate deductible, coinsurance and out-of-pocket maximum to prescription drugs, which changes the arithmetic entirely for a biologic (5)
• Nearly 40 percent of individual marketplace plans available for 2026 included a copay accumulator policy, so manufacturer copay help may not count toward your deductible (7)
• Health insurance for Crohn's disease here means the United States system; if you are elsewhere, treat this as questions to ask rather than rules that apply to you

Why Health Insurance for Crohn's Disease Hits Harder Than Average

Crohn's sits in the small group of conditions where the plan you pick can change your annual spending by thousands of dollars. In the Crohn's & Colitis Foundation's cost-of-IBD analysis, direct costs averaged $22,987 per member per year for IBD patients against $6,956 for matched non-IBD controls, with out-of-pocket costs of $2,213 versus $979 (6). That is before anyone is prescribed a biologic.

The biologic effect is larger still. Fewer than 20 percent of the patients in that analysis were on biologic therapy, yet they incurred 2 to 3 times the total annual cost of care (6). If you take infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab or a biosimilar, you are in the part of the distribution where plan design matters most.

Mean cost in the first year after diagnosis was $26,555 (6), so many of us face the most expensive year of care while we still know least about how our plan works. The conclusion is uncomfortable but simple: for anyone on or starting a biologic, the plan with the lowest premium is frequently the most expensive plan overall.

Everything below describes the United States. Availability, naming and reimbursement differ enormously by country, so readers elsewhere should use this as a map of what to ask their own system.

The Four Numbers That Decide What You Actually Pay

Four figures together determine your spending: premium, deductible, coinsurance or copay, and out-of-pocket maximum. HealthCare.gov is explicit that you should compare estimated total yearly cost rather than the premium alone, because cost sharing can add more to the total than the premium itself does (5). For Crohn's patients, that is usually what happens.

Premium, Deductible, Coinsurance and Out-of-Pocket Maximum

The premium is what you pay monthly whether or not you use care, the deductible is what you pay before the plan shares costs, and coinsurance is your percentage share afterward, a copay being a flat amount instead. The out-of-pocket maximum matters most, because it is the real ceiling: once you reach it, the plan pays 100 percent of covered services for the rest of the plan year (5). For 2027, CMS set that cap at $12,000 for self-only and $24,000 for other than self-only coverage, roughly 13.2 percent above the 2026 parameters of $10,600 and $21,200 (1). Those are legal ceilings, not what every plan charges, and many plans set lower caps.

The Separate Prescription Drug Deductible Most People Miss

Here is the part that catches people out. A plan may set a separate deductible, coinsurance and out-of-pocket maximum that applies only to prescription drugs (5). A plan advertising a $1,500 medical deductible can also carry a distinct drug deductible, and your biologic runs through that second one.

So do this on paper: add twelve monthly premiums to the drug out-of-pocket maximum, then add the medical out-of-pocket maximum if it is tracked separately. That total is a realistic worst-case year on an infusion or injection. Run it for every plan you are considering, because the ranking frequently reverses the ranking by premium.

Read the Drug Formulary Before You Enroll

A formulary is the plan's list of covered drugs and the tier each one sits on. It is separate from the benefits summary, and it is the single most useful file to find before enrolling with Crohn's disease.

Finding Your Biologic on the Tier List

On a marketplace plan page, look for a link labelled formulary, drug list or prescription drug coverage, usually a PDF. For an employer plan, ask HR or the pharmacy benefit manager for the document itself rather than the summary grid. Search it for your drug by generic name, and separately for the biosimilars: plans increasingly prefer a particular biosimilar, so a formulary may cover an infliximab biosimilar at a better tier than the brand you are infused with today.

Specialty Tier, Step Therapy and Prior Authorization

Most Crohn's biologics land on a specialty tier, where your share is often a percentage of the drug cost rather than a flat copay, so your exposure scales with the price of the therapy until you hit the cap.

Formularies also mark utilisation management: usually PA for prior authorization, ST for step therapy and QL for quantity limits. Step therapy means a cheaper drug may have to fail before the plan covers the one you and your gastroenterologist chose. Both are a cost and delay risk you can see before enrolling, which beats discovering it in February. If a plan imposes them, our guide to prior authorization and appeals covers pushing back.

Site of Care Rules for Infusions

If you are on an infused therapy, check whether the plan restricts the site of care. Some plans steer infusions away from hospital outpatient departments toward standalone or home infusion, and will pay differently or not at all for the setting you use now. Then verify two network questions by name: your gastroenterologist, and your specific infusion centre. Directories go out of date, so confirm with the practice as well as the plan.

Before the deadline, call the plan's member services line with a written list:

• Is my drug, by generic name, on the formulary for the coming year, and on which tier?
• Is my share a flat copay or a percentage, and is there a per-fill cap?
• Is there a separate prescription drug deductible and out-of-pocket maximum?
• Does the drug require prior authorization or step therapy?
• Are infusions restricted to particular sites of care?
• Are my gastroenterologist and my infusion centre in network?

Copay Assistance and the Accumulator Trap

Manufacturer copay assistance can cut what you hand over at the pharmacy or infusion centre to very little. A copay accumulator adjustment policy quietly undoes that: the plan accepts the manufacturer's money but does not credit it toward your deductible or out-of-pocket maximum (7). You feel covered all spring, then the assistance runs out and your deductible is untouched.

This is common. According to The AIDS Institute's 2026 analysis, nearly 40 percent of individual marketplace plans available for 2026 included such a policy, and at least one plan with one was sold in 31 states (7).

State law helps, but unevenly. The same report counts 26 states plus the District of Columbia and Puerto Rico restricting the practice. Those laws reach only state-regulated plans, generally individual and small group rather than large employer coverage, leaving an estimated 26 million people, or 19 percent of commercial enrollees, protected (7). If your coverage is a large self-funded employer plan, a law in your state may not reach you.

A late 2023 federal district court ruling also required non-grandfathered plans to count copayments toward the deductible and out-of-pocket maximum where no generic equivalent exists, but the report states HHS has not enforced it (7). The ruling exists and the practice continues.

So the action step is narrow: ask the plan, in writing, whether manufacturer copay assistance counts toward the deductible and out-of-pocket maximum, and keep the answer. Our walkthrough of the Skyrizi copay card shows how one programme is structured, including the annual limits that make accumulator exposure matter.

Metal Tiers and Subsidies: Why Silver Can Beat Bronze

Marketplace plans are grouped by the share of covered costs the plan pays on average: bronze about 60 percent, silver 70 percent, gold 80 percent and platinum 90 percent (2). That looks like a straightforward trade of premium against coverage. What bends it is cost-sharing reductions, available only on silver plans: with extra savings applied, a silver plan pays 73 to 96 percent of covered costs depending on household income (2), which can make a subsidised silver plan better than gold, not just better than bronze.

The 2027 figures show the size of the effect. CMS set the reduced out-of-pocket cap at $4,000 for household income from 100 up to 200 percent of the federal poverty level, and $9,600 above 200 and up to 250 percent (1). Against a standard $12,000 self-only cap, a $4,000 ceiling is a different financial year for anyone with predictable high drug spend, so check whether you qualify before ruling out silver on premium alone.

One trade-off deserves naming rather than dismissing: bronze and catastrophic plans are the ones compatible with a health savings account (2). Tax-advantaged saving for predictable medical spending has real value, so this is a judgement call against the subsidy you would give up.

Enrollment Windows and a Side-by-Side Comparison Method

Deadlines cannot be appealed, so write them down first.

Marketplace, Employer and Medicare Timelines

Marketplace open enrollment runs November 1 to January 15 (3). State-run exchanges set their own dates and several extend past January 15, so confirm the deadline for your own state.

Medicare open enrollment runs October 15 to December 7, with coverage generally starting January 1 (4). If you are moving onto Medicare on a biologic, raise the Part B versus Part D question with your team well before December.

Employer timing is set by the employer, so there is no national date to rely on (3). Ask HR for the full plan documents and the formulary, not just the comparison grid on the benefits portal. If accommodations are part of the same conversation, our guide to workplace accommodations and the ADA covers that separately.

A Worksheet Approach to Comparing Two or Three Plans

Comparison is much easier as a table than a memory exercise. Fill in one column per plan:

| Item | Plan A | Plan B | | --- | --- | --- | | Annual premium (12 months) | | | | Medical deductible | | | | Separate drug deductible | | | | Biologic covered, and on what tier | | | | Cost share: flat copay or percentage | | | | Prior authorization or step therapy required | | | | Drug out-of-pocket maximum | | | | Total out-of-pocket maximum | | | | Copay accumulator policy (in writing) | | | | Gastroenterologist in network | | | | Infusion site in network | | | | Worst-case year: premiums plus caps | | |

The bottom row is the one to compare. In our community we have seen people switch on the strength of a $90 monthly premium difference and lose far more to a specialty tier percentage and an untouched drug deductible.

If the only affordable plan still leaves a gap, that is a planning problem rather than a dead end. Manufacturer assistance programmes, independent patient assistance foundations, the plan's financial counsellors and your infusion centre's billing office are all worth approaching before the year starts rather than after the first bill, and our article on financial planning with Crohn's disease goes through them in order. None of this is how anyone wants to spend a November, but an afternoon with two formularies and a worksheet is the highest-value unpaid work many of us do all year.

Frequently Asked Questions

Is the cheapest health insurance plan ever the right choice with Crohn's disease?

Sometimes, but only if the arithmetic supports it. If you are not on a biologic, are in sustained remission and expect low use, a low-premium plan can work. If you are on or starting one, cost sharing often adds more than the premium does (5), and biologic patients incurred 2 to 3 times the total annual cost of care (6). Compare worst-case annual totals, not premiums.

What is a copay accumulator and how do I know if my plan has one?

It is a policy where the plan accepts manufacturer copay assistance but does not credit it toward your deductible or out-of-pocket maximum (7). Nearly 40 percent of individual marketplace plans available for 2026 included one (7). The reliable way to find out is to ask the plan in writing whether assistance counts toward both figures, and keep the reply.

Will my biologic be covered if I switch plans?

Coverage is plan-specific, so check the new formulary by generic name before enrolling, biosimilars included. Confirm the tier, whether your share is a percentage or a flat copay, and whether prior authorization or step therapy applies. A new plan can require a fresh prior authorization for a drug you have taken for years.

Why would a silver plan cost less than a bronze plan?

Because cost-sharing reductions apply only to silver plans, raising what the plan pays from about 70 percent to between 73 and 96 percent of covered costs depending on income (2). For 2027 the reduced out-of-pocket cap is $4,000 at 100 to 200 percent of the federal poverty level and $9,600 above 200 up to 250 percent, against a $12,000 standard self-only cap (1). With high predictable drug spend, that usually beats a lower bronze premium.

Does any of this apply if I am not in the United States?

The structure does not, but the questions do. Metal tiers, ACA caps and copay accumulators are United States features. Wherever you live, ask the same things: is my drug on the national or insurer list, does a cheaper drug have to fail first, which hospital or infusion unit is covered, and what is my realistic annual out-of-pocket exposure.

References

1. Centers for Medicare & Medicaid Services, Center for Consumer Information and Insurance Oversight. Premium Adjustment Percentage, Maximum Annual Limitation on Cost Sharing, Reduced Maximum Annual Limitation on Cost Sharing, and Required Contribution Percentage for the 2027 Benefit Year. January 29, 2026. Read guidance
2. HealthCare.gov. Marketplace plan categories: Bronze, Silver, Gold, Platinum and Catastrophic. 2026. Read article
3. HealthCare.gov. Open Enrollment Period (glossary). 2026. Read article
4. Medicare.gov. Joining a plan. 2026. Read article
5. HealthCare.gov. Your total costs for health care: premiums, deductibles and out-of-pocket costs. 2026. Read article
6. Park KT, Ehrlich OG, Allen JI, et al. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflammatory Bowel Diseases, 2020;26(1):1-10. Read study
7. The AIDS Institute. Shortchanged: The Patient Impact of Copay Accumulator Policies in 2026. February 2026. Read report